Century Therapeutics, Inc. 8-K

What Happened
Century Therapeutics, Inc. announced (8‑K filed March 26, 2026) that its shelf registration on Form S‑3 (filed July 10, 2025) became effective January 9, 2026 and it filed a prospectus supplement dated March 26, 2026 for its existing "at the market" (ATM) equity offering program. The ATM program allows the company to sell up to $150,000,000 of common stock through its sales agent (Cowen and Company, LLC, predecessor to TD Securities (USA) LLC).

Key Details

• New shelf registration (Form S‑3, File No. 333-288616) effective January 9, 2026.
• Prospectus supplement dated March 26, 2026 covers the existing ATM Program with a $150,000,000 aggregate offering capacity.
• $18,380,259 of common stock has been sold under the ATM Program to date; $131,619,741 remains available.
• Sales Agreement dated July 1, 2022 remains in effect; legal opinion from Goodwin Procter LLP filed as Exhibit 5.1.

Why It Matters
This filing updates investors on the company’s available equity financing capacity. The refreshed S‑3 and prospectus supplement keep Century’s $150M ATM facility usable going forward, providing a ready mechanism to raise capital by selling shares when management chooses. For investors, the key facts are how much has already been sold ($18.38M) and how much equity capacity remains (~$131.62M), which can affect dilution risk and the company’s cash runway depending on future use.